Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials
European Heart Journal · 07.12.2024 · 45 (46) · 4902-4916
DOI: 10.1093/eurheartj/ehae596 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Heart Journal, online erschienen am 02.09.2024. Verfasst von Renate B Schnabel und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Stroke. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BMBF, German Ministry of Education and Research, Berlin, Germany, German Centre for Cardiovascular Research, Berlin, Germany.
Abstract (Originalsprache)
Background and Aims The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation.
Methods
These pre-specified analyses of the NOAH-AFNET 6 (n = 2534 patients) and ARTESiA (n = 4012 patients) trials compared anticoagulation with no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischaemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and death.
Results
In patients with vascular disease (NOAH-AFNET 6, 56%; ARTESiA, 46%), stroke, myocardial infarction, systemic or pulmonary embolism, or cardiovascular death occurred at 3.9%/patient-year with and 5.0%/patient-year without anticoagulation (NOAH-AFNET 6), and 3.2%/patient-year with and 4.4%/patient-year without anticoagulation (ARTESiA). Without vascular disease, outcomes were equal with and without anticoagulation (NOAH-AFNET 6, 2.7%/patient-year; ARTESiA, 2.3%/patient-year in both randomized groups). Meta-analysis found consistent results across both trials (I2heterogeneity = 6%) with a trend for interaction with randomized therapy (pinteraction = .08). Stroke/SE behaved similarly. Anticoagulation equally increased major bleeding in vascular disease patients [edoxaban, 2.1%/patient-year; no anticoagulation, 1.3%/patient-year; apixaban, 1.7%/patient-years; no anticoagulation, 1.1%/patient-year; incidence rate ratio 1.55 (1.10–2.20)] and without vascular disease [edoxaban, 2.2%/patient-year; no anticoagulation, 0.6%/patient-year; apixaban, 1.4%/patient-year; no anticoagulation, 1.1%/patient-year; incidence rate ratio 1.93 (0.72–5.20)].
Conclusions
Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
- German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Luebeck, Hamburg, Germany.
- Atrial Fibrillation NETwork (AFNET), Mendelstraße 11, 48149 Muenster, Germany.
- Cardiology Department, Hospital Universitario La Luz, Madrid, Spain.
- Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
- Institute of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
ORCID-Profile: Renate B Schnabel, Juan Benezet-Mazuecos, Nina Becher, Alexander Fierenz, Shun Fu Lee, Dan Atar, Gregory Chlouverakis, A John Camm, Emmanuel Simantirakis, Valentina Kutyifa, Eloi Marijon, Lena Rivard, Ulrich Schotten, Susanne Sehner, Tobias Toennis, Cecilia Linde, Antonia Zapf, Jeff S Healey, Paulus Kirchhof
Förderung
- BMBF
- German Ministry of Education and Research, Berlin, Germany
- German Centre for Cardiovascular Research, Berlin, Germany
- Daiichi Sankyo Europe
- European Union CATCH ME
- AFFECT EU
- MAESTRIA
- British Heart Foundation
Zitieren
APA
Schnabel, R. B., Benezet-Mazuecos, J., Becher, N., McIntyre, W. F., Fierenz, A., Lee, S. F., Goette, A., Atar, D., Bertaglia, E., Benz, A. P., Chlouverakis, G., Birnie, D. H., Dichtl, W., Blomstrom-Lundqvist, C., Camm, A. J., Erath, J. W., Simantirakis, E., Kutyifa, V., Lip, G. Y. H., …, & Kirchhof, P. (2024). Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials. European Heart Journal, 45(46), 4902-4916. https://doi.org/10.1093/eurheartj/ehae596
Vancouver
Schnabel RB, Benezet-Mazuecos J, Becher N, McIntyre WF, Fierenz A, Lee SF, et al. Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials. European Heart Journal. 2024;45(46):4902-4916. doi:10.1093/eurheartj/ehae596
BibTeX
@article{Schnabel2024,
author = {Schnabel, Renate B and Benezet-Mazuecos, Juan and Becher, Nina and McIntyre, William F and Fierenz, Alexander and Lee, Shun Fu and Goette, Andreas and Atar, Dan and Bertaglia, Emanuele and Benz, Alexander P and Chlouverakis, Gregory and Birnie, David H and Dichtl, Wolfgang and Blomstrom-Lundqvist, Carina and Camm, A John and Erath, Julia W and Simantirakis, Emmanuel and Kutyifa, Valentina and Lip, Gregory Y H and Mabo, Philippe and Marijon, Eloi and Rivard, Lena and Schotten, Ulrich and Alings, Marco and Sehner, Susanne and Toennis, Tobias and Linde, Cecilia and Vardas, Panos and Granger, Christopher B and Zapf, Antonia and Lopes, Renato D and Healey, Jeff S and Kirchhof, Paulus},
title = {Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials},
journal = {European Heart Journal},
year = {2024},
volume = {45},
number = {46},
pages = {4902--4916},
doi = {10.1093/eurheartj/ehae596}
}
EUVIMED